Compared with the model group, the combined treatment of DSF/Cu and DTX increased CD3+ T cells in the spleen of tumor-bearing mice (p < 0.05), among which the proportion of CD8+ T cells was significantly increased (p < 0.001), and the number of CD4+ T cells increased with no statistical difference (Fig. 6A). The gene discussed is CD8A; the disease is neoplasm.